First New Treatment for Rare Brain Cancer in 20 Years Added to Australia's PBS
核心洞察
Vorasidenib (Voranigo) becomes the first targeted treatment for IDH-mutant astrocytoma (搜索) and oligodendroglioma (搜索) listed on Australia's Pharmaceutical Benefits Scheme in over two decades.
The PBS listing reduces the cost from $28,000 per month to a maximum of $25 per script, benefiting approximately 135 Australians diagnosed annually.
The oral therapy targets mutations in IDH1 (搜索) or IDH2 (搜索) genes, blocking mutated proteins that drive cancer growth and potentially slowing disease progression.
The first breakthrough treatment for a rare, incurable brain cancer in more than 20 years has been listed on Australia's Pharmaceutical Benefits Scheme (PBS), offering new hope to patients who previously faced limited options and prohibitive costs.
Vorasidenib, marketed under the brand name Voranigo by Servier, was added to the subsidised medicines scheme on August 1, slashing the out-of-pocket cost from $28,000 per month to a maximum of $25 per script — or $7.70 for concession card holders. The oral therapy is indicated for patients with IDH-mutant astrocytoma (搜索) and oligodendroglioma (搜索), slow-growing brain tumours driven by genetic mutations.
"This is the first new treatment in 20 years being listed for a rare brain cancer, which can slow disease progression," Health Minister Mark Butler said. "Listing Voranigo will benefit around 135 Australians diagnosed with this rare, incurable brain cancer each year, offering these patients a treatment option that can give them precious time."
A Disease Striking Young Adults
IDH-mutant gliomas are the most common malignant primary brain tumours in adults under 50, with an estimated 3,230 Australians currently living with the condition, according to Servier. Patients are typically diagnosed between the ages of 20 and 45, and the disease's degenerative effects include seizures, cognitive changes, physical disability, and loss of independence over many years.
Prior to vorasidenib's availability, treatment options were confined to surgery, ongoing monitoring, and radiotherapy or chemotherapy to slow progression. There remains no cure.
Mechanism of Action and Clinical Role
Vorasidenib targets cancers harbouring mutations in the IDH1 (搜索) or IDH2 (搜索) genes, which cause abnormal proteins to form and contribute to tumour growth. By blocking these mutated proteins, the drug can slow or halt cancer progression.
"Access to vorasidenib through the PBS provides clinicians with a targeted treatment option, adding another tool to the toolbox and supporting greater choice when discussing treatment options with patients," said Associate Professor Jim Whittle, medical oncologist at the Peter MacCallum Cancer Centre. "Caring for these patients often involves balancing long-term disease control with preserving neurological function and quality of life."
Patient Impact
Victorian mother Leah Ferguson, 38, was diagnosed with the cancer two and a half years ago, just months after giving birth to her daughter Lulu. Following surgery, doctors were forced to leave behind a small section of tumour in a part of her brain too dangerous to operate on.
Ferguson began taking vorasidenib two years ago and said the treatment has helped allay anxiety surrounding her remaining tumour. "It's that sense of hope to have an option not to have to think about it every day and to know that I'm doing all I can to delay any progression," she said. "The main thing I wanted was more time with my daughter ... I can have this quality of time and just think about doing the fun things, living with Lulu and my family."
Safety Considerations
According to Servier guidelines, vorasidenib can result in increased liver enzymes, with other side effects including fatigue, headache, diarrhoea, nausea, muscle aches, and stiffness. Liver function should be monitored before and throughout treatment, and patients are advised to consult their specialist about treatment options.
Broader Significance
Australian Brain Tumour Collaborative spokesperson Craig Cardinal described the listing as a "significant milestone," while emphasising that access to treatment represents only one dimension of care. "People living with brain cancer and their families also need coordinated multidisciplinary care, psychosocial support and practical services throughout every stage of their diagnosis," he said.
Servier Australia and New Zealand general manager Mélanie Chamaux said the listing "represents a collective achievement of the healthcare system recognising therapeutic progress and the meaningful difference innovative medicines can make for patients, their families and the broader community."
The PBS listing also includes expanded access to adalimumab and infliximab for children with Crohn's disease, reducing costs from approximately $500 to $25 per script for more than 400 paediatric patients.